Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free
Relmada Therapeutics NASDAQ RLMD
$3.69 0.05 1.36%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 17 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

111.07M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
106.97M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.24
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
30.10M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-10.87 %
Upcoming events Relmada Therapeutics All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Relmada Therapeutics

Stock analysis Relmada Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-1.15 35.52
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
1.30 13.63
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-1.03 17.42
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.04 0.37
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-113.59 8.90

Price change Relmada Therapeutics per year

20.60$ 40.00$
Min Max

Summary analysis Relmada Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Relmada Therapeutics

Revenue and net income Relmada Therapeutics

All parameters
Stock news Relmada Therapeutics All news
1 February в 23:50

Relmada Therapeutics Shares Hit 52-Week High After Execs Buy Shares

1 February в 23:50

Relmada Therapeutics Shares Hit 52-Week High After Execs Buy Shares

4 January в 19:35

Relmada Therapeutics Shares Slide as Medical Chief Exits

4 January в 19:35

Relmada Therapeutics Shares Slide as Medical Chief Exits

20 September 2023 в 16:50

Relmada Therapeutics Shares Rise 18% After Positive Trial Data for REL-1017

20 September 2023 в 16:50

Relmada Therapeutics Shares Rise 18% After Positive Trial Data for REL-1017

10 December 2022 в 00:05

Relmada Therapeutics Shares Rebound From All-Time Low

10 December 2022 в 00:05

Relmada Therapeutics Shares Rebound From All-Time Low

8 December 2022 в 19:20

Relmada Therapeutics Shares Plumb New Depths After Lead Program Setback >RLMD

8 December 2022 в 19:20

Relmada Therapeutics Shares Plumb New Depths After Lead Program Setback >RLMD

8 December 2022 в 16:45

Relmada Therapeutics shares decline 40% on Thursday

8 December 2022 в 16:06

Relmada Therapeutics Shares Slide Premarket on Study Failure >RLMD

8 December 2022 в 16:06

Relmada Therapeutics Shares Slide Premarket on Study Failure >RLMD

13 October 2022 в 17:00

Relmada Therapeutics Shares Plummet on Phase 3 Study Failure >RLMD

13 October 2022 в 17:00

Relmada Therapeutics Shares Plummet on Phase 3 Study Failure >RLMD

13 October 2022 в 14:42

Relmada Therapeutics' REL-1017 Fails in Phase 3 Major Depressive Disorder Monotherapy Study

13 October 2022 в 14:36

Relmada Therapeutics' REL-1017 Fails in Phase 3 Major Depressive Disorder Monotherapy Study

23 February 2022 в 21:55

Relmada Therapeutics Shares Rise 8% After Depression Treatment Results

23 February 2022 в 21:55

Relmada Therapeutics Shares Rise 8% After Depression Treatment Results

23 February 2022 в 15:05

Relmada Therapeutics Sees Positive Topline Results for Depression Treatment

About company Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead program is REL-1017, is a new chemical entity and novel N-methyl-D-aspartate receptor channel blocker for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is based in Coral Gables, Florida.
Address:
2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Company name: Relmada Therapeutics
Issuer ticker: RLMD
ISIN: US75955J4022
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2014-10-09
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.relmada.com

On which stock exchange are Relmada Therapeutics (RLMD) stocks traded?

Relmada Therapeutics (RLMD) stocks are traded on NASDAQ.

What is the ticker of Relmada Therapeutics stocks (RLMD)?

The stock ticker of Relmada Therapeutics’s stocks or in other words, the code is RLMD. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Relmada Therapeutics (RLMD) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Relmada Therapeutics (RLMD) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Relmada Therapeutics (RLMD) stocks traded?

Relmada Therapeutics (RLMD) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Relmada Therapeutics (RLMD) stocks today?

The current price of Relmada Therapeutics stocks on 02.05.2024 is 3.69 dollars. per share.

What is the dynamics of Relmada Therapeutics (RLMD) stocks from the beginning of the year?

Relmada Therapeutics (RLMD) quotes have increased by -15.56% from the beginning of the year up to 3.69 dollars. per 1 stocks.

How much did Relmada Therapeutics (RLMD) stocks increase in мае 2024?

This month Relmada Therapeutics (RLMD) quotes have increased by 0% to 3.69 dollars. per share.

How much are Relmada Therapeutics (RLMD) stocks worth?

Today, on October, 02.05.2024 Relmada Therapeutics’s (RLMD) stocks cost 3.69 dollars..

What is the market capitalization of Relmada Therapeutics (RLMD)?

Capitalization is the market value of Relmada Therapeutics (RLMD) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 02.05.2024, the market capitalization of Relmada Therapeutics (RLMD) is estimated at about 111066059 dollars.